Physician profile
Kathy Ramirez
NPI 1043738008
$1,897.86
in general payments reported to CMS, 2019-2025
12 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $899 · 2022: $345 · 2023: $336 · 2024: $72.61 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,031.00 | 2021-2023 | Axonics, Bulkamid |
| Astellas Pharma US INC | $297.11 | 2021-2024 | Myrbetriq |
| Sumitomo Pharma America, INC. | $176.88 | 2023-2025 | Gemtesa |
| Urovant Sciences INC | $117.45 | 2021-2022 | |
| Boston Scientific Corporation | $102.83 | 2021-2025 | Axonics |
| Urogen Pharma, INC. | $52.96 | 2025 | |
| Olympus America INC. | $32.84 | 2025 | Itind System |
| Pfizer INC. | $24.70 | 2025 | |
| Telix Pharmaceuticals | $22.14 | 2025 | Illuccix |
| Tolmar, INC. | $17.62 | 2024 | |
| Coloplast Corp | $14.84 | 2025 | |
| Ambu INC. | $7.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.